360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Cadence Pharmaceuticals Inc

Type: Company

Name: Cadence Pharmaceuticals Inc

Nationality: United States

Web Address: http://www.cadencepharm.com/

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Shares of CADX Up 29.0% Since Uptrend Call on Shares

(Comtex SmarTrend(R)) SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on March 21st, 2013 at $5.53. In approximately 3 months, Cadence Pharmaceuticals has returned 29.05% as of today's recent price of $7.13. In the past 52 ... [Published Individual.com - Jun 14 2013]

Entities: Stocks, Cadence Pharmaceuticals Inc, Comtex

First reported Jun 13 2013 - Updated Jun 13 2013 - 2 reports

Form 4 CADENCE PHARMACEUTICALS For: Jun 12 Filed by: BARKER SAM L

StreetInsider.com - Form 4 CADENCE PHARMACEUTICALS For: Jun 12 Filed by: BARKER SAM L ... [Published Street Insider - Jun 13 2013]

Entities: Cadence Pharmaceuticals Inc

First reported Jun 11 2013 - Updated Jun 11 2013 - 2 reports

Cadence Pharmaceuticals Inc

Form 4 CADENCE PHARMACEUTICALS For: Jun 10 Filed by: Lloyd-Smith Malcolm

StreetInsider.com - Form 4 CADENCE PHARMACEUTICALS For: Jun 10 Filed by: Lloyd-Smith Malcolm ... [Published Street Insider - Jun 11 2013]

Entities: Cadence Pharmaceuticals Inc

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Cadence Pharmaceuticals Shares Sinking Lower, Down 2.3%

(Financial News Network On) Cadence Pharmaceuticals (NASDAQ:CADX) is one of today's biggest movers, down 2.3% to $7.53. The Dow Jones Industrial Average is now trading 1.1% higher to 15,200 and the S&P is trading 0.9% higher to 1,637. Cadence Pharm ... [Published Individual.com - Jun 07 2013]

Entities: Cadence Pharmaceuticals Inc, Stocks, Dow Jones Industrial Average

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Cadence Pharmaceuticals Shares Sinking...

Cadence Pharmaceuticals (NASDAQ:CADX) is one of today's biggest movers, down 2.3% to $7.53. The Dow Jones Industrial Average is now trading 1.1% higher to 15,200 and the S&P is trading 0.9% higher to 1,637. Cadence Pharmaceuticals, Inc. is a biopharmaceutical ... [Published Financial News Network online - Jun 07 2013]

Entities: Cadence Pharmaceuticals Inc, Stocks, acute pain, Biopharmaceutical

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Uptrend Call Working As Cadence Pharmaceuticals Stock Rises 39.2% (CADX)

(Comtex SmarTrend(R)) SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on March 21st, 2013 at $5.53. In approximately 3 months, Cadence Pharmaceuticals has returned 39.19% as of today's recent price of $7.69. In the past 52 ... [Published Individual.com - Jun 07 2013]

Entities: Cadence Pharmaceuticals Inc, Comtex

First reported Jun 05 2013 - Updated Jun 05 2013 - 2 reports

Piper Jaffray Companies

Cadence Pharmaceuticals Coverage Initiated by Analysts at Piper Jaffray (CADX)

Equities research analysts at Piper Jaffray initiated coverage on shares of Cadence Pharmaceuticals (NASDAQ: CADX) in a research note issued to investors on Wednesday, StockRatingsNetwork reports. The firm set a “neutral” rating on the stock.The analysts ... [Published The Utah People's Post - Jun 05 2013]

Entities: Cadence Pharmaceuticals Inc, Piper Jaffray Companies, opioid, Stocks, NSAIDs

First reported Jun 05 2013 - Updated Jun 05 2013 - 1 reports

UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue Gaining Traction

In a report published on Wednesday, Piper Jaffray analyst David Amsellem initiated coverage on Cadence Pharmaceuticals (NASDAQ: CADX) with a Neutral rating and a price target of $7.00.In the report, Piper Jaffray noted, "In our survey of nearly three ... [Published Benzinga.com - Jun 05 2013]

Entities: Cadence Pharmaceuticals Inc, Piper Jaffray Companies, opioid, NSAIDs

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through the VA National Formulary

/PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), announced today that the Department of Veterans Affairs has made OFIRMEV® (acetaminophen) injection available on the VA National Formulary (VANF). The VANF is a list of products (drugs and ... [Published Longitude Capital - Jun 03 2013]

Entities: Cadence Pharmaceuticals Inc, Paracetamol, National Formulary, Patient, hepatic

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Cadence Pharmaceuticals Makes a Move: Up 6.4%

(Financial News Network On) Cadence Pharmaceuticals (NASDAQ:CADX) is a company whose shares are active, trading 6.4% higher to $7.08. The Dow is up 0.3% to 15,163 and the S&P is currently trading fractionally lower to 1,628. In the past 52 weeks, C ... [Published Individual.com - Jun 03 2013]

Entities: Cadence Pharmaceuticals Inc, fractionation, Standard & Poor's

First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

Cadence Pharmaceuticals, Inc. (CADX) - Strategic SWOT Analysis Review - new company profile report

- Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company principally engaged in in-licensing, developing and commercialization of proprietary pharmaceuticals, and product candidates that are principally used in the hospital setting. Cadence ... [Published TransWorldNews - Jun 03 2013]

Entities: Cadence Pharmaceuticals Inc, SWOT Analysis, Corporate Strategy, acute pain

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Cadence Pharmaceuticals Shares Up 20.2% Since SmarTrend's Buy Recommendation (CADX)

(Comtex SmarTrend(R)) SmarTrend identified an Uptrend for Cadence Pharmaceuticals (NASDAQ:CADX) on March 21st, 2013 at $5.53. In approximately 2 months, Cadence Pharmaceuticals has returned 20.18% as of today's recent price of $6.64. In the past 52 ... [Published Individual.com - May 31 2013]

Entities: Cadence Pharmaceuticals Inc, Stocks, Comtex

Quotes

In the report, Piper Jaffray noted, "In our survey of nearly three dozen surgeons, the vast majority polled use a multi-modal approach to post operative pain (i e., opioids, local analgesics like bupivacaine, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen). Given this backdrop, and the risks related to opioids, it was not surprising to us that just under half of those we polled are already using Ofirmev (albeit still in a minority of patients), and over a third of those polled are planning to use Ofirmev more frequently in the next 6-12 months. Given this feedback, and the fact that Ofirmev is not an opioid and does not have the bleeding risks that hamper NSAIDs, we believe U S sales north of $225M by 2015 and peak sales of $450M-$500M are realistic."

UPDATE: Piper Jaffray Initiates Cadence Pharmaceuticals at Neutral, Generics Likely to Continue G ... [Published Benzinga.com - Jun 05 2013]

"We believe that the availability of OFIRMEV on the VANF demonstrates the VA's recognition of the clinical value that OFIRMEV can offer to patients and physicians in the treatment of acute pain and fever. Now, clinicians practicing at VA facilities have access to OFIRMEV for use in a multimodal approach to pain management in the hospital setting" said Ted Schroeder, President and CEO of Cadence

Cadence Pharmaceuticals Announces the Availability of OFIRMEV® (acetaminophen) Injection through ... [Published Longitude Capital - Jun 03 2013]

...while also supporting our risk management objectives through geographic diversification," said Ted Schroeder, President and CEO of Cadence. "Additionally, the termination of our supply agreement with Baxter marks the amicable end to our collaboration for the development and initial commercial supply of OFIRMEV."

Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OF ... [Published Longitude Capital - Jun 03 2013]

I responded as follows: "ALS is a disease in which neurons are progressively destroyed in the spine. Other than in the hippocampus, I am not aware of any region in the body in which neurons are regenerated. In ALS, neurons are progressively destroyed in the spine through a mechanism that is not well understood. For spontaneous improvement to occur, the body would have to create new neurons in the spine which seems unlikely based on current knowledge. Hopefully, this is what CUR's neural stem cells are doing. This is what makes the Ted Harada experience so interesting as clearly his condition improved."

SmithOnStocks Opines On Biotechnology Stocks, May 24, 2013 [Published Seeking Alpha - May 27 2013]

More Content

sort by: Date \| Relevance
Shares of CADX Up 29.0% Since Uptrend Call on S... [Published Individual.com - Jun 14 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 12 File... [Published Street Insider - Jun 13 2013]
Stock Investors Sell Off Shares of Cadence Phar... [Published Individual.com - Jun 13 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 10 File... [Published Street Insider - Jun 11 2013]
Form 4 CADENCE PHARMACEUTICALS For: Jun 07 File... [Published Street Insider - Jun 11 2013]
Charting a resilient bull market [Published TD Ameritrade - Jun 11 2013]
Hedge Funds Are Buying EXACT Sciences Corporati... [Published InsiderMonkey.com - Jun 10 2013]
Is Array Biopharma Inc (ARRY) Going to Burn The... [Published InsiderMonkey.com - Jun 10 2013]
SmithOnStocks Opines: June 9, 2013 [Published Seeking Alpha - Jun 10 2013]
Cadence Pharmaceuticals Shares Sinking Lower, D... [Published Individual.com - Jun 07 2013]
Cadence Pharmaceuticals Shares Sinking... [Published Financial News Network online - Jun 07 2013]
Uptrend Call Working As Cadence Pharmaceuticals... [Published Individual.com - Jun 07 2013]
Cadence Pharmaceuticals Coverage Initiated by A... [Published The Utah People's Post - Jun 05 2013]
Research Analysts’ New Coverage for June, 5th (... [Published American Banking News - Jun 05 2013]
Cadence Pharmaceuticals Coverage Initiated at P... [Published American Banking News - Jun 05 2013]
After-Hours Buzz: VeriFone, Vera Bradley, Franc... [Published CNBC - Jun 05 2013]
UPDATE: Piper Jaffray Initiates Cadence Pharmac... [Published Benzinga.com - Jun 05 2013]
Cadence Pharmaceuticals Announces the Availabil... [Published Longitude Capital - Jun 03 2013]
Cadence Pharmaceuticals Announces Strategic Pla... [Published Longitude Capital - Jun 03 2013]
Cadence Pharmaceuticals Makes a Move: Up 6.4% [Published Individual.com - Jun 03 2013]
Cadence Pharmaceuticals, Inc. (CADX) - Strategi... [Published TransWorldNews - Jun 03 2013]
Cadence Pharmaceuticals Shares Up 20.2% Since S... [Published Individual.com - May 31 2013]
Dohmen’s BioSoteria Calls for Abstracts for its... [Published PRWeb - May 31 2013]
Cadence Pharmaceuticals' CEO Presents at Deutsc... [Published Seeking Alpha - May 30 2013]
Shares of Cadence Pharmaceuticals Under Pressur... [Published Individual.com - May 29 2013]

Blogs

sort by: Date \| Relevance
Up And Down The Ladder… Job Changes [Published Pharmalot - Mar 15 2013] Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them . Don’t be shy. Everyone wants ...
Court Report [Published Patent Docs - Feb 10 2013] By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cadence Pharmaceuticals, Inc. et al. v. Sandoz Inc. 3:13-cv-00733; filed February 5, 2013 in the District Court of New Jersey•Plaintiffs: ...
Rockwell Automation SVP Sells 34K Shares and 4 ... [Published Wall St. Cheat Sheet - Jan 25 2013] Domain Parters Vii L P who is 10% Owner at Cadence Pharmaceuticals Inc. ( NASDAQ:CADX ), sold 25,354 shares at $5.11 per share for a total value of $129,559. The shares recently traded at $5.45, up $0.34, or 6.65% since the insider sale. Current ...
Court Report [Published Patent Docs - Jan 21 2013] By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cadence Pharmaceuticals, Inc. et al. v. Fresenius Kabi USA, LLC 3:13-cv-00139; filed January 17, 2013 in the Southern District of Cal ...
OFIRMEV (Acetaminophen) Injection, Solution [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jan 16 2013] Updated Date: Jan 15, 2013 EST ...

Press Releases

sort by: Date \| Relevance
Cadence Pharmaceuticals To Host Conference Call... [Published PR Newswire: Health - Apr 25 2013]
Sharp Increase in FDA Drug Approvals a Major Fa... [Published Marketwire - Breaking News Releases - Mar 20 2013]
Cadence Pharmaceuticals Appoints Stephen L. New... [Published PR Newswire: General Business - Mar 14 2013]
Cadence Pharmaceuticals Announces the Availabil... [Published PR Newswire: Health - Mar 12 2013]
Cadence Pharmaceuticals Reports Fourth Quarter ... [Published Financial Services - Mar 07 2013]